

**South Dakota Department of Social Services, Division of Medicaid Services  
Pharmacy & Therapeutics (P&T) Committee Meeting Minutes**

Friday, September 27, 2019

1:00 – 3:00 pm CT

**Members and DSS Staff**

Michelle Baack, MD		Kelley Oehlke, PharmD	X
Dana Darger, RPh	X	Lenny Petrik, PharmD	X
James Engelbrecht, MD	X	Timothy Soundy, MD	
Deidre Van Gilder, PharmD	X	Mike Jockheck, DSS Staff	X
Mikal Holland, MD		Sarah Akers, DSS Staff	
Richard Holm, MD	X	Bill Snyder, DSS Staff	X
Bill Ladwig, RPh, Chair	X		

**Administrative Business**

Darger called the meeting to order at 1:08 PM. The minutes of the June meeting were presented. Ladwig made a motion to approve. Oehlke seconded the motion. Motion was approved unanimously.

**Prior Authorization Update (PA) and Statistics**

The Committee reviewed the PA activity report from April 1, 2019 to June 30, 2019. A total of 1,991 PAs were reviewed of which 333 requests (16.73%) were received via telephone and 1,133 requests (56.91%) were received via fax, and 525 (26.37%) were reviewed via electronically. The Committee also reviewed the PA Approval Reviews with 96% to 82% approvals. Van Gilder questioned the daptomycin and insulin quantity limit reviews.

**Analysis of the Top 15 Therapeutic Classes and Drug Spend**

The Committee reviewed the top 15 therapeutic classes by total cost of claims from April 1, 2019 to June 30, 2019. The top five therapeutic classes based on paid amount were atypical antipsychotics, anticonvulsants, disease-modifying anti-rheumatic agents, amphetamines, and respiratory and CNS stimulants. The top 15 therapeutic classes make up 24.06% of total claims. The Committee also reviewed the top 50 drugs based on total claims cost and number of claims. The top 50 drugs by claims cost make up 6.85% of total claims.

**Old Business**

Committee reviewed CGRP utilization comparing 1Q19 vs 2Q19. Utilization increased slightly. There were no utilization for Orlistat during 2Q19. Committee requested to review utilization for both classes again at the next meeting.

Committee reviewed ADHD/ADD utilization for 2Q19 for members 26 years and older. Committee requested to review this class when a committee member with psychiatry background is available. Committee inquired how other Medicaid states are managing this class. Ladwig requested the MME level of the 18 recipients taking ADD/ADHD medication with concomitant utilization with opioid/benzodiazepine/antipsychotic.

Committee reviewed opioid outcomes from the opioid initiatives. Utilization level and MME levels indicate a decreased trend.

## **New Business**

The Committee reviewed utilization for albuterol inhalers and deliberated on quantity limits for this class. Committee requested utilization for patients routinely using two or more inhalers per month. Utilization to include prescriber and concomitant maintenance medication usage.

The Committee reviewed buprenorphine utilization to potentially loosen buprenorphine criteria in consequence of opioid utilization management initiatives. Initially, PA implemented on buprenorphine was due to potential misuse for pain management instead of using it for opioid withdrawal. After discussion, Ladwig made a motion to remove PA on buprenorphine. Engelbrecht seconded the motion. Motion was approved unanimously.

In support of the Federal Support Act, concomitant opioid utilization with benzodiazepine and opioid utilization with antipsychotics were provided to the Committee for review. Jockheck confirmed South Dakota Medicaid met minimum requirements with message only currently in place for opioids/benzodiazepine. After discussion, Ladwig made a motion to set soft edits for opioids/benzodiazepine and opioid/antipsychotic. Holm seconded the motion. Motion was approved unanimously.

The Committee reviewed the recommendation from the Ad Hoc Committee on Pain Management and Prescription Drug Abuse, titled "Effective management of Acute Pain" by the South Dakota State Medical Association. Jockheck reminded Committee on the current opioid edits for opioid naive and on long acting and short acting opioids. Engelbrecht and Darger commented since opioid management strategies are already in place for South Dakota Medicaid, if Committee members wanted to recommend additional opioid initiatives, to provide them at future meetings.

The Committee reviewed the tetracycline therapy class, especially new drugs Seysara and Nuzyra. There was no public testimony provided. After drug and utilization review, Committee recommended adding step therapy to Seysara to the current Oracea/Solodyn step therapy. Ladwig made a motion to add Seysara to step therapy and Holm seconded the motion. Motion was approved unanimously.

The Committee reviewed the multiple sclerosis (MS) therapy class, especially new drugs Mayzent and Mavenclad. There was no public testimony provided. After drug and utilization review, Petrik made a motion to add Mayzent and Mavenclad to the current MS PA criteria with neurology consult. Ladwig seconded the motion. Motion was approved unanimously.

Snyder provided an update regarding the Committee's recommendation from the June meeting. DSS continues to evaluate the recommendation.

The next meeting is scheduled for December 13, 2019. Tentative meeting dates for next year are March 13, 2020 and June 5, 2020. Ladwig made a motion to adjourn the meeting and Holm seconded the motion. The motion passed unanimously and the meeting adjourned at 3:22 PM.